Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.37 |
| ▸ | PTGES | O14684 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 2/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3933897 | 0.85 | KDM4E (0.46) | ALDH1A1SMN1; SMN2KDM4ETSHRPOLB | |
| SCHEMBL3945810 | 0.81 | KDM4E (0.42) | ALDH1A1SMN1; SMN2KDM4EKMT2ATSHR | |
| SCHEMBL3944819 | 0.76 | AR (0.37) | SCN9AAR | |
| SCHEMBL1065575 | 0.75 | KMT2A (0.48) | ALDH1A1SMN1; SMN2KDM4EKMT2ATSHR | |
| SCHEMBL13122355 | 0.73 | AR (0.43) | PARP1AR | |
| SCHEMBL20543771 | 0.71 | ALDH1A1 (0.48) | ALDH1A1KDM4EKMT2APOLBSCN9A | |
| SCHEMBL21117726 | 0.71 | ALDH1A1 (0.48) | ALDH1A1KDM4EKMT2APOLBSCN9A | |
| SCHEMBL7342562 | 0.71 | ALDH1A1 (0.48) | ALDH1A1KDM4EKMT2APOLBSCN9A | |
| Hydrochloric Acid SCHEMBL6379482 | 0.70 | ALDH1A1 (0.47) | ALDH1A1KDM4EKMT2APOLBSCN9A | |
| SCHEMBL6781351 | 0.69 | KDM4E (0.54) | ALDH1A1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082372-A1 | Arylmethylene Substituted N-Acyl-Beta-Amino Alcohols | BAYER SCHERING PHARMA AG (DE) | 2009-03-26 | — | — | US | disclosed |
| WO-2009013354-A1 | ARYLMETHYLENE SUBSTITUTED N-ACYL-β-AMINO ALCOHOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082372-A1 | Arylmethylene Substituted N-Acyl-Beta-Amino Alcohols | FSHR, SHBG, NAT1 | ALDH1A1 388/4885SMN1; SMN2 2238/4885KDM4E 1126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.